Treatment of AIDS-related Kaposi’s Sarcoma With Low-dose Radiotherapy – Follow-up on 2,305 Tumours

2021 ◽  
Vol 41 (8) ◽  
pp. 3871-3874
Author(s):  
HANS CHRISTIAN WULF ◽  
IDA M. HEERFORDT
Keyword(s):  
Kaposi's Sarcoma ◽  
Low Dose ◽  
Kaposi’S Sarcoma ◽  
Low Dose Radiotherapy

Laryngeal Kaposi's sarcoma in patients with AIDS

1996 ◽  
Vol 110 (11) ◽  
pp. 1034-1037 ◽  
Author(s):  
George Mochloulis ◽  
Richard M. Irving ◽  
Henry R. Grant ◽  
Robert F. Miller
Keyword(s):  
Kaposi's Sarcoma ◽  
Systemic Chemotherapy ◽  
Low Dose ◽  
Upper Airway ◽  
Kaposi’S Sarcoma ◽  
Hiv Disease ◽  
Low Dose Radiotherapy ◽  
Immunodeficiency Virus ◽  
University College London ◽  
Advanced Hiv Disease

AbstractOver a period of 10 years 17 human immunodeficiency virus(HIV)-infected patients with laryngeal Kaposi's sarcoma were seen and treated at University College London Hospitals. All patients had advanced HIV disease. Their presentation was with symptoms of upper airway obstruction in the majority of cases and the diagnosis was made by fibreoptic examination of the larynx. Biopsy was associated with brisk haemorrhage in one patient, who required a temporary tracheostomy, and was not performed in the other 16 cases. The commonest site of laryngeal involvement was the supraglottis in 11 patients, with glottic lesions noted in eight patients: subglottic lesions were seen in only three. Treatment of laryngeal Kaposi's sarcoma was, in general, conservative, five patients received low dose radiotherapy to the larynx and 10 were treated with systemic chemotherapy for disseminated Kaposi's sarcoma. Laryngeal Kaposi's sarcoma did not contribute to patient mortality.

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

1984 ◽  
Vol 2 (10) ◽  
pp. 1115-1120 ◽  
Author(s):  
L J Laubenstein ◽  
R L Krigel ◽  
C M Odajnyk ◽  
K B Hymes ◽  
A Friedman-Kien ◽  
...  
Keyword(s):  
Immune Deficiency ◽  
Complete Remission ◽  
Partial Remission ◽  
Kaposi's Sarcoma ◽  
Opportunistic Infections ◽  
Kaposi’S Sarcoma ◽  
Response Duration ◽  
Median Response ◽  
Stage Disease

An epidemic of disseminated Kaposi's sarcoma in male homosexuals has recently been described. Forty-one evaluable patients with epidemic Kaposi's sarcoma were treated with etoposide. The majority of these patients had early stage disease, no prior opportunistic infections, and no prior therapy. Twelve patients (30%) achieved complete remission, 19 (46%) partial remission, and ten (24%) no response. With follow-up time to 31 months, the median response duration is nine months. The median survival of patients with complete and partial remissions has not been reached. A combination of doxorubicin (Adriamycin, Adria Laboratories, Columbus, Ohio), bleomycin, and vinblastine (ABV) was used in 31 evaluable patients with epidemic Kaposi's sarcoma. The majority of these patients had late stage disease, prior opportunistic infections, or had failed prior treatment. Seven patients (23%) achieved complete remission, 19 (61%) partial remission, and five (61%) no response. With follow-up time to 24 months, the median response duration is eight months. The projected median survival for all patients treated with ABV is nine months. Both regimens were well tolerated, with an overall response rate of 76% for etoposide and 84% for ABV. However, while successfully treating the Kaposi's sarcoma, the underlying immune deficiency in these patients has persisted. Future treatments of Kaposi's sarcoma will need to focus on reversing the underlying immune incompetence as well as controlling the malignant manifestations of Kaposi's sarcoma arising in relation to the acquired immune deficiency syndrome.

scholarly journals Spinal cord compression in b-thalassemia: follow-up after radiotherapy

1998 ◽  
Vol 116 (6) ◽  
pp. 1879-1881 ◽  
Author(s):  
Silvana Fahel da Fonseca ◽  
Maria Stella Figueiredo ◽  
Rodolfo Delfini Cançado ◽  
Fernando Nakandakare ◽  
Roberto Segreto ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Case Report ◽  
Spinal Cord Compression ◽  
Low Dose ◽  
Extramedullary Hematopoiesis ◽  
Cord Compression ◽  
Hematologic Disorders ◽  
Rare Syndrome ◽  
Low Dose Radiotherapy

CONTEXT: Spinal cord compression due to extramedullary hematopoiesis is a well-described but rare syndrome encountered in several clinical hematologic disorders, including <FONT FACE="Symbol">b</font>-thalassemia. CASE REPORT: We report the case of a patient with intermediate <FONT FACE="Symbol">b</font>-thalassemia and crural paraparesis due to spinal cord compression by a paravertebral extramedullary mass. She was successfully treated with low-dose radiotherapy and transfusions. After splenectomy, she was regularly followed up for over four years without transfusion or recurrence of spinal cord compression. DISCUSSION: Extramedullary hematopoiesis should be investigated in patients with hematologic disorders and spinal cord symptoms. The rapid recognition and treatment with radiotherapy can dramatically alleviate symptoms.

Kaposi's Sarcoma in Young Patients Treated with Orthovoltage Irradiation and Having a Minimum Follow-Up of Forty-Six Years

2009 ◽  
Vol 95 (3) ◽  
pp. 325-328 ◽  
Author(s):  
Stefano Pergolizzi ◽  
Anna Santacaterina ◽  
Michele Gaeta ◽  
Alfredo Blandino
Keyword(s):  
Renal Failure ◽  
Radiation Therapy ◽  
Chronic Renal Failure ◽  
Clinical Outcome ◽  
Kaposi's Sarcoma ◽  
Young Patients ◽  
Kaposi’S Sarcoma ◽  
Orthovoltage Radiotherapy

Purpose To describe the clinical outcome and to evaluate the role of orthovoltage radiotherapy in the treatment of young (less than 30 years old) Mediterranean men with Kaposi's sarcoma. Patients and methods We reviewed the records of 198 consecutive patients with Kaposi's sarcoma treated with orthovoltage radiation therapy at our department between January 1920 and December 1987. Result We found three young shepherds, aged less than 30 years, with an available follow-up ranging from 45 to 67 years. One patient died at the age of 84 years of chronic renal failure while suffering from cutaneous Kaposi's sarcoma; two patients are still alive with recurrent Kaposi's sarcoma. Conclusions We presume that an indolent form of Kaposi's sarcoma may occur in young men. This very indolent form can be controlled for the duration of the patient's life by judiciously applied radiation therapy.

scholarly journals 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S175-S175
Author(s):  
Sheena Knights ◽  
Susana Lazarte ◽  
Radhika Kainthla ◽  
Demi Krieger ◽  
Mitu Bhattatiry ◽  
...  
Keyword(s):  
African American ◽  
Drug Use ◽  
Cancer Diagnosis ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
The United States ◽  
T1 Stage ◽  
Race Ethnicity ◽  
Iv Drug Use

Abstract Background Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularly African-American men in the South. Methods A retrospective electronic medical record review was conducted using integrated inpatient and outpatient data in EPIC from PHHS. We included all individuals with a diagnosis of HIV and Kaposi’s sarcoma between January 1, 2009 and December 31, 2018 based on ICD-9/10 codes. We collected demographic information, HIV history, variables related to HIV and KS diagnosis, treatment and outcomes data for each patient. We calculated hazard ratios using Cox proportional hazards modeling. Results We identified 252 patients with KS. 95% of patients were male, and the majority were MSM (men who have sex with men; 77% of all patients). 35% of patients were Hispanic, 34% were African-American and 31% were Caucasian. Over half (56%) of patients were funded through Ryan White or were uninsured. The median CD4 count and viral load at the time of cancer diagnosis were 44 and 73,450, respectively. 24% of patients were confirmed to have died by the end of the study time frame. However, due to loss to follow-up, 35% of the cohort had an unknown vital status at the time of the final chart review. Variables most strongly associated with mortality were >2 hospitalizations in the first 6 months of cancer diagnosis (aHR=4.93, P = 0.0003), IV drug use (aHR=3.61, P = 0.0009), and T1 stage of KS (aHR= 2.13, P = 0.0264). African American patients had lower survival than Caucasian or Hispanic patients, with a 5-year survival of 69%, 81% and 80% respectively, although this did not reach statistical significance (aHR 1.77, P = 0.1396). Conclusion We describe a large cohort of patients with HIV and HHV-8-related disease, who are predominantly of minority race/ethnicity, uninsured, and have advanced HIV disease. Factors associated with mortality include Black/African-American ethnicity, number of hospitalizations, IV drug use and T1 stage of KS. Our mortality analysis is limited due to high lost to follow-up rates, so we suspect overall mortality in our cohort is higher than currently reported. Disclosures Ank E. Nijhawan, MD, MPH, Gilead Sciences, Inc.: Research Grant.

Sign in / Sign up

Export Citation Format

Share Document